ERBB2 and breast carcinoma: Multivariate analysis indicated that N positive (P = 0.019, HR = 4.233, 95% CI 1.623 to 6.759), histological grade III (P = 0.036, HR = 2.729, 95% CI 1.206 to 6.795) and non-pCR after neoadjuvant therapy (P = 0.027, HR = 2.306, 95% CI 1.252 to 5.439) were independent risk factors for recurrence and metastasis of HR-/HER2 + breast cancer, while AR status was not a predictive factor (P = 0.151).